Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Optimization of a high-cell-density polyethylenimine transfection method for rapid protein production in CHO-EBNA1 cells.

Stuible M, Burlacu A, Perret S, Brochu D, Paul-Roc B, Baardsnes J, Loignon M, Grazzini E, Durocher Y.

J Biotechnol. 2018 Sep 10;281:39-47. doi: 10.1016/j.jbiotec.2018.06.307. Epub 2018 Jun 7.

PMID:
29886030
2.

Treatment options for progressive multifocal leukoencephalopathy in HIV-infected persons: current status and future directions.

Loignon M, Toma E.

Expert Rev Anti Infect Ther. 2016;14(2):177-91. doi: 10.1586/14787210.2016.1132162. Epub 2016 Jan 4. Review.

PMID:
26655489
3.

Cerebral microsporidiosis manifesting as progressive multifocal leukoencephalopathy in an HIV-infected individual - a case report.

Loignon M, Labrecque LG, Bard C, Robitaille Y, Toma E.

AIDS Res Ther. 2014 Jul 15;11:20. doi: 10.1186/1742-6405-11-20. eCollection 2014.

4.

Combination antiretroviral therapy and chronic HIV infection affect serum retinoid concentrations: longitudinal and cross-sectional assessments.

Loignon M, Brodeur H, Deschênes S, Phaneuf D, Bhat PV, Toma E.

AIDS Res Ther. 2012 Feb 1;9:3. doi: 10.1186/1742-6405-9-3.

5.

Putative chemopreventive molecules can increase Nrf2-regulated cell defense in some human cancer cell lines, resulting in resistance to common cytotoxic therapies.

Hu L, Miao W, Loignon M, Kandouz M, Batist G.

Cancer Chemother Pharmacol. 2010 Aug;66(3):467-74. doi: 10.1007/s00280-009-1182-7. Epub 2009 Nov 26.

PMID:
19940992
6.

Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapy.

Loignon M, Miao W, Hu L, Bier A, Bismar TA, Scrivens PJ, Mann K, Basik M, Bouchard A, Fiset PO, Batist Z, Batist G.

Mol Cancer Ther. 2009 Aug;8(8):2432-40. doi: 10.1158/1535-7163.MCT-08-1186. Epub 2009 Jul 28.

7.

The QKI-6 and QKI-7 RNA binding proteins block proliferation and promote Schwann cell myelination.

Larocque D, Fragoso G, Huang J, Mushynski WE, Loignon M, Richard S, Almazan G.

PLoS One. 2009 Jun 11;4(6):e5867. doi: 10.1371/journal.pone.0005867.

8.

Stable high volumetric production of glycosylated human recombinant IFNalpha2b in HEK293 cells.

Loignon M, Perret S, Kelly J, Boulais D, Cass B, Bisson L, Afkhamizarreh F, Durocher Y.

BMC Biotechnol. 2008 Aug 27;8:65. doi: 10.1186/1472-6750-8-65.

9.

The bioactivity and receptor affinity of recombinant tagged EGF designed for tissue engineering applications is defined by the nature and position of the tags.

Boucher C, St-Laurent G, Loignon M, Jolicoeur M, De Crescenzo G, Durocher Y.

Tissue Eng Part A. 2008 Dec;14(12):2069-77. doi: 10.1089/ten.tea.2008.0037.

PMID:
18652537
11.

Technical report: optimal quantity of saline for epidural pressure waveform analysis.

de Médicis E, Pelletier J, Martin R, Loignon MJ, Tétrault JP, Laroche L.

Can J Anaesth. 2007 Oct;54(10):818-21.

PMID:
17934163
13.

XRCC3 depletion induces spontaneous DNA breaks and p53-dependent cell death.

Loignon M, Amrein L, Dunn M, Aloyz R.

Cell Cycle. 2007 Mar 1;6(5):606-11. Epub 2007 Mar 30.

PMID:
17351336
14.
15.

Overexpression of SERTAD3, a putative oncogene located within the 19q13 amplicon, induces E2F activity and promotes tumor growth.

Darwish H, Cho JM, Loignon M, Alaoui-Jamali MA.

Oncogene. 2007 Jun 21;26(29):4319-28. Epub 2007 Jan 29.

PMID:
17260023
16.

Longitudinal changes in HIV-specific IFN-gamma secretion in subjects who received Remune vaccination prior to treatment interruption.

Huang KH, Boisvert MP, Chung F, Loignon M, Zarowny D, Cyr L, Toma E, Bernard NF.

J Immune Based Ther Vaccines. 2006 Nov 28;4:7.

17.

FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion.

Benlimame N, He Q, Jie S, Xiao D, Xu YJ, Loignon M, Schlaepfer DD, Alaoui-Jamali MA.

J Cell Biol. 2005 Nov 7;171(3):505-16.

18.

Oncolytic activity of vesicular stomatitis virus in primary adult T-cell leukemia.

Césaire R, Olière S, Sharif-Askari E, Loignon M, Lézin A, Olindo S, Panelatti G, Kazanji M, Aloyz R, Panasci L, Bell JC, Hiscott J.

Oncogene. 2006 Jan 19;25(3):349-58.

PMID:
16186807
19.

Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis.

Xu ZY, Loignon M, Han FY, Panasci L, Aloyz R.

J Pharmacol Exp Ther. 2005 Aug;314(2):495-505. Epub 2005 Apr 20.

PMID:
15843498
20.

Repression of DNA repair mechanisms in IRF-4-expressing and HTLV-I-infected T lymphocytes.

Mamane Y, Loignon M, Palmer J, Hernandez E, Césaire R, Alaoui-Jamali M, Hiscott J.

J Interferon Cytokine Res. 2005 Jan;25(1):43-51.

PMID:
15684621
21.

Imatinib sensitizes CLL lymphocytes to chlorambucil.

Aloyz R, Grzywacz K, Xu ZY, Loignon M, Alaoui-Jamali MA, Panasci L.

Leukemia. 2004 Mar;18(3):409-14.

PMID:
14712290
22.

Cdc25A-inhibitory properties and antineoplastic activity of bisperoxovanadium analogues.

Scrivens PJ, Alaoui-Jamali MA, Giannini G, Wang T, Loignon M, Batist G, Sandor VA.

Mol Cancer Ther. 2003 Oct;2(10):1053-9.

23.

Statin-associated myopathy with normal creatine kinase levels.

Toma E, Loignon M.

Ann Intern Med. 2003 Jun 17;138(12):1007-8; author reply 1008-9. No abstract available.

PMID:
12809465
25.
26.
27.
28.

Supplemental Content

Loading ...
Support Center